11 Nov 2025
6m
Spyre Therapeutics is developing a basket of therapies (α4β7, TL1A, and IL-23) that are meant to have a greater half-life and work better in combination that current therapies for IBD and rheumatology
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.